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Introduction
Critically ill patients are at high risk for delirium, occurring in up to 80% of mechanically ventilated patients. (1) In such patients, a longer duration of delirium is associated with impaired cognitive function, lasting >12 months after discharge.(1) Such cognitive impairment reduces quality of life and return to work, while increasing institutionalization and healthcare costs. (2;3) Despite the importance of this neurocognitive morbidity, there are limited pharmacological interventions to reduce delirium and long-term cognitive impairment. (4) Both animal and human data offer indirect evidence that neuroinflammation, with associated oxidative damage and apoptosis, is an important part of the pathophysiology of delirium in the ICU and subsequent long-term cognitive impairment. (5) (6) (7) (8) Severe sepsis is a prototype of systemic inflammation, including neuroinflammation. A randomized controlled trial appropriate for evaluating the effect of statins in critically ill septic patients is the large, multi-centered trial known as Statins for Acutely Injured Lungs from Sepsis (SAILS), conducted by the ARDS Network (ARDSNet), which evaluated the short-term effects of rosuvastatin versus placebo on mortality and ventilator-free days. (23) In conjunction with the SAILS trial, we conducted an ancillary study to assess if rosuvastatin reduced delirium in the ICU and improved cognitive function at 6-and 12-month follow-up.
Methods

This ancillary study of the SAILS trial is part of the NIH-funded ARDSNet Long-Term
Outcomes Study (ALTOS) that included prospective evaluation of daily delirium status in the ICU (primary outcome) and cognitive function at 6-and 12-month follow-up (secondary outcomes). Initially, daily delirium status in the ICU and cognitive assessments were conducted only for patients recruited from 12 of 37 hospitals participating in the SAILS trial. Based on new data demonstrating that statin use was associated with reduced odds of delirium in the ICU, (24) the ARDS Network amended the SAILS protocol, expanding assessment of daily delirium status in the ICU and cognitive outcomes at 6 and 12 month follow-up to 23 additional hospitals.
Institutional review boards at each participating site approved this study, with informed consent obtained from each patient or their proxy (when the patient was incapable of consent).
Study Procedures and Eligible Patients
Details of the SAILS eligibility criteria and study intervention have been reported previously,(23) and are briefly summarized herein. From March 18, 2010 to September 30, 2013 , patients were randomized (with concealed allocation) in permuted blocks of 8, with stratification by hospital study site, via a web-based system to receive daily enteral rosuvastatin (a 40-mg loading dose and daily 20-mg dose) or a similar-appearing placebo, administered from the time of randomization until the earliest of death, 3 days after ICU discharge, or study day 28.(23) SAILS was stopped early due to futility, after recruiting 745 of its 1000 patient sample size, with no significant differences in short-term mortality, ventilator-free days, and ICU-free days. The first 75 patients in the current analysis were co-enrolled in ARDSNet's prior 1000-patient EDEN study, a randomized trial of initial trophic vs. full enteral feeding for up to 6 days after ARDS, that demonstrated no significant difference in short-term outcomes, (23) For evaluation of SAILS survivors' cognitive function at 6 and 12 month follow-up, the following additional exclusion criteria were applied: <18 years old, non-English speaking, homeless or pre-existing cognitive impairment (evaluated based on patients' status prior to hospitalization using medical record review and/or interview with the patient and/or proxy).
Patient loss during 6-and 12-month follow-up was minimized through established cohort retention methods. (29) (30) (31) (32) (33) (34) (35) Primary Outcome: Daily Delirium Status in the ICU Daily delirium status in the ICU was evaluated by research or clinical personnel, blinded to treatment allocation, using the validated and reliable Confusion Assessment Method for the ICU (CAM-ICU).(36-38) As per CAM-ICU methodology,(36) patients who were non-responsive to verbal stimulation (e.g., Richmond Agitation Sedation Scale (RASS)(39) score of -4 or -5), referred to hereafter as "coma," were excluded from delirium assessment for that day. Based on this test battery, a binary assessment of overall "cognitive impairment" was conservatively defined, as in prior research,(26) as having either 1 cognitive test score ≥2 standard deviations (SD) below population norms (i.e. bottom 2.5%) or at least 2 test scores ≥1.5 SD below norms (i.e. bottom 6.7%).(41) Additionally, individual results on specific cognitive tests are presented as both continuous scores and binary outcomes (≥1.5 SD below norm). The following cognitive domains were evaluated in the test battery: (1) executive function, evaluated via the Hayling Sentence Completion Test scaled score (range: 1 to 10; higher is better);(42) (2) language, evaluated via a Verbal Fluency Test total score (higher score is better);(43) (3) verbal reasoning and concept formation, evaluated via the Similarities age-adjusted scaled score (range: 1 to 19; higher is better) from the Wechsler Adult Intelligence Scale-Third Edition;(44;45) and (4) attention and working memory evaluated via the Digit Span age-adjusted scaled score (range: 1 to 19; higher is better) from the Wechsler Adult Intelligence Scale-Third Edition(44;45) (5) immediate and delayed memory, evaluated via the Logical Memory I and II age-adjusted scaled scores (range: 1 to 19; higher is better) from the Wechsler Memory Scale-Third Edition;(44;45)
Statistical analysis
Descriptive statistics were used to compare patient and intensive care data across the two treatment groups. The primary outcome, daily delirium status up to 28 days after randomization, was compared across treatment groups using a joint survival model that allowed for recurrent events (i.e., the repeated within-subject daily delirium status) and for a terminating event (death or ICU discharge).(46) The recurrent event model included a main effect of treatment only, quantified as the relative hazard of delirium on any day in the ICU comparing rosuvastatin vs. placebo groups. The terminating event model included two main effects: randomized treatment group and the type of terminating event (death or ICU discharge), and their interaction. A random intercept linked the models for daily delirium status within a patient over time and the possible terminating event. Patients alive and in the ICU at 28 days were administratively censored.
The primary analysis was performed on the available data using the intention-to-treat principle, with patients contributing to the model on days when the CAM-ICU was administered and delirium was able to be assessed (i.e. no coma). The joint survival model used in the primary analysis is valid under the missing at random assumption, with missingness as follows: CAM-ICU never available for 3 (1%) of 275 patients and for 527 (25%) of 2089 non-comatose patient days plus 230 patient days in which coma status was not available. A sensitivity analysis was performed with multiple imputation of the missing coma and delirium status using regression models that included information on baseline patient and intensive care data, daily intensive care data, and coma and delirium status from the prior day.
Continuous and binary secondary outcomes were compared at 6 and 12 months using linear or logistic random intercept regression models, respectively, that included the main effect of time only. Treatment effects were estimated separately at 6 and 12 months using the same models with addition of an effect of treatment group and its interaction with time. Sensitivity analyses included repeating the statistical analyses of the 6 and 12 outcomes for only the cohort of patients with both delirium and cognitive impairment data.
Pre-specified sub-group analyses were performed for the primary and secondary analyses to evaluate if the treatment effect differed based on age, shock at baseline, use of statins at baseline (obtained for a subset of SAILS patients), APACHE III severity of illness score, and being in the ICU on treatment on study day 7 (reflecting more prolonged exposure to rosuvastatin). Post-hoc analyses completed for both the primary and secondary outcomes including adjusting for potential clustering of patient outcomes within hospitals and the adjusting for known risk factors for delirium. (47;48) The sample size for these analyses was based on the available patients at the participating sites during the eligible enrollment period, as described above. All analyses were conducted according to an a priori written statistical analysis plan, and performed using R version 3.1.3 and SAS version 9.3 statistical software. The primary analysis was conducted using the "frailtypack" package within R and secondary analyses were conducted using Proc Mixed and Proc NLMixed(49) within SAS. A two sided P<0.05 was considered significant. This trial is registered with ClinicalTrials.gov (NCT00979121 and NCT00719446).
Role of the Funding Source
All researchers are independent of the funding bodies. The funding bodies had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication. DMN and EC had full access to all the outcomes data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Results
Participating hospitals recruited 329 SAILS patients, of which 164 (50%) were randomized to rosuvastatin. Of these 329 patients, 275 (84%) were enrolled at a hospital that performed delirium outcome assessments. Of these 275 patients, 3 (1%) were excluded due to missing delirium assessment data (2 patients from rosuvastatin group and 1 from placebo), leaving 137 (50%) and 135 (50%) randomized to rosuvastatin and placebo, respectively, for analysis of the primary outcome of delirium in the ICU (Figure 1 ). For the secondary outcomes related to 6-and 12-month cognitive function, among the 329 SAILS patients, 60 (18%) died prior to 6-month follow-up (34 [20%] in rosuvastatin and 26 [16%] in placebo group, p=0.45), 75 (23%) met ALTOS exclusion criteria, and 5 (1.5%) were enrolled prior to starting the ALTOS study, leaving 189 eligible patients, of which 83 (44%) and 106 (56%) were randomized to rosuvastatin and placebo, respectively ( Figure 1 ).
Patient characteristics
Baseline patient and ICU characteristics were similar between the rosuvastatin versus placebo groups across the patient cohorts evaluated in this analysis (Table 1 and Appendix Table 1 ). In the overall cohort of 329 patients, characteristics included a mean (SD) age of 52 (16) (48/329) required hemodialysis, with a mean (SD) duration of mechanical ventilation and hospital stay of 10 (10) and 21 (13) days, respectively. As also observed in SAILS,(23) the statin group had worse renal and hepatic organ-failure free days (Table 1 ). In the cohort evaluated for 6-and 12-month cognitive impairment, the average (SD) years of education was 13 (2.3) vs. 13 (2.6) in the rosuvastatin vs. placebo groups. During follow-up, of 174 patients, 3 (<2%) had a stroke, 6 (<4%) had any hospitalization for neurologic cause, and 26 (15%) commenced any type of psychiatric medication.
Delirium in the ICU and Cognitive Impairment at 6 and 12 Months
Of the 272 patients evaluated daily for delirium in the ICU, 195 (72%) ever had delirium, with a mean (SD) of 32% (30%) of daily patient assessments being delirium and 14% (21%) being coma. Of 192 delirious patients with coincident RASS sedation assessments, 10 (5%) had exclusively hyperactive (RASS >0), 112 (58%) exclusively hypoactive (RASS ≤0), and 70 (37%) mixed delirium during their ICU stay. At 6-and 12-month follow-up, respectively, 37% (48/130) and 29% (43/148) of evaluated survivors had evidence of overall cognitive impairment (as defined in Methods), without significant improvement over time (p=0.17) ( Table 2 ). At 6-month follow-up, the domains of cognition most commonly impaired were ( Figure 2 vs. 12 months, p=0.003).
Comparison of Rosuvastatin versus Placebo
For rosuvastatin vs. placebo groups, patients had similar mean (SD) proportions of assessments with delirium (34% (30%) vs. 31% (29%), p =0.39) and coma (13% (20%) vs. 15% (22%), p=0.34). For the primary outcome of daily delirium status in the ICU, there was no significant effect of rosuvastatin versus placebo, with a hazard ratio for delirium (95% confidence interval) of 1.14 (0.92 -1.41, p=0.22) . The results of the primary analysis were consistent after multiple imputation for missing delirium status. There was no patient subgroup identified which demonstrated a significant benefit of rosuvastatin vs. placebo for reducing delirium.
For each of the secondary outcomes of cognitive function at 6-and 12-month follow-up, there was no significant beneficial effect of rosuvastatin vs. placebo ( Figure 3 shows 6-month results).
There were significant associations between randomization to rosuvastatin and worse delayed memory, with a worse mean (SD) continuous score (Logical Memory II test score: 7.9 (3.3) vs.
8.8 (2.7), p=0.017) and a greater percentage of patients with impaired delayed memory (24% vs. 10%, p=0.050) ( Table 3) .
Across the subgroup analyses, there were no significant effects of rosuvastatin vs. placebo, except as reported herein. For the subgroup of patients in the ICU at day 7 or longer, at 6-month follow-up, those receiving rosuvastatin vs. placebo had higher odds of impairment in language (evaluated via verbal fluency test), and lower (i.e., worse) scaled scores for both immediate and delayed memory (Logical Memory I and II tests). These differences were not significant at 12-months, with the exception of delayed memory in which the rosuvastatin vs. placebo group had higher (i.e., better) scaled scores.
Post-hoc analyses of primary and secondary outcomes accounting for clustering of patient outcomes within hospitals (Appendix Table 2 ) and adjusting for known delirium risk factors (Appendix Table 3 ) did not materially change the results for the primary outcome. For the secondary outcomes, the only change was with the Similarities (verbal reasoning and concept formation) age-scaled score, for which the adjusted average treatment effect was significantly Page 13 of 31 lower (i.e., worse) in rosuvastatin vs. placebo (-1.43 [-267, -0.18 ], p=0.025) at 6 month followup only (Appendix Table 3 ).
As reported previously,(23) evaluation of adverse events in the SAILS trial demonstrated no significant difference in rosuvastatin vs. placebo in the occurrence of elevated creatine kinase levels (16 vs. 13, p=0.65) and alanine aminotransferase levels (10 vs. 12, p=0.39), but there were significantly more patients with elevated aspartate aminotransferase levels (16 vs. 2 patients, p<0.001). Additionally, hyperthermia, a serious adverse event, occurred in three patients in the rosuvastatin group.
Discussion
In this ancillary study of the randomized, double-blinded, placebo-controlled SAILS trial of rosuvastatin versus placebo for sepsis-associated ARDS, 72% of patients ever had delirium in the ICU and approximately one-third had cognitive impairment at 6-and 12-month follow-up, with executive function being the only cognitive domain demonstrating significant improvement over time. Despite indirect evidence from pre-clinical studies and results from two observational ICU studies of statin use, this trial demonstrated no benefit of randomization to rosuvastatin in reducing delirium in the ICU or cognitive impairment at 6-and 12-month follow-up.
Comparison with Other Studies
The 72% delirium prevalence in this study is similar to the 77% reported in a prior two-site observational study of statins and delirium in patients with acute respiratory failure or shock. (19) Not surprisingly, the prevalence was lower (36%) in the other observational study of statins in delirium that evaluated all consecutive patients admitted to a single ICU in which only 42% of patients were mechanically ventilated,(20) and lower than the pooled prevalence in a recent meta-analyses of critically ill patients.(50) The prevalence of cognitive impairment at 6-and 12-month follow-up in this report was very similar to a separate patient cohort from ARDSNet's EDEN trial that used an identical cognitive test battery and definition of cognitive impairment.(26) This prevalence was also very similar to a two-site cohort of patients with respiratory failure or shock evaluated at 3-and 12-month follow-up, using a different cognitive testing battery. (1) The findings that rosuvastatin did not improve delirium in the ICU conflicts with two rigorously designed observational studies,(19;20) mentioned above, with these prior results demonstrating strong and consistent associations of statin use with reduced daily delirium in the ICU, particularly for septic patients early in their ICU stay. (19) The high overall prevalence of delirium in our study or heterogeneity in baseline risk for delirium within our study cohort may have affected study results.(19;20) Additionally, differences in findings compared to the observational studies may reflect unmeasured confounders biasing the prior studies-a limitation minimized with the randomized, double-blinded design of our study. Such a difference in findings was also observed in evaluating statins' effect on short-term mortality and other infection-related complications in patients with infection and sepsis, whereby prior observational studies (51) (52) (53) reported improved outcomes that were not replicated in the SAILS randomized trial.(23) However, as discussed subsequently, these differing results also may have arisen because of the greater lipophilic properties (and hence, greater crossing of the blood brain barrier and tissue penetration) of simvastatin, used in 78% and 88% of patients in the 2 prior observational studies, (19;20;54) versus rosuvastatin used in SAILS. Additionally, a prior observational study (20) suggested that inflammation (measured by C-reactive protein (CRP)) may be a potential mediator of the beneficial association between statins and delirium, but in the present study, no differences were found in CRP levels in rosuvastatin vs. placebo groups (except on study day 9). In patients taking statins at baseline and randomized to placebo, there may be concern regarding rebound inflammation after cessation of statins. (55;56) However, such a concern may be less likely given similar CRP levels between treatment groups in this study; however, such data on baseline status use were only recorded in a subset of patients, preventing full evaluation of this issue.
Notably, the associations between randomization to rosuvastatin vs. placebo and worse delayed memory (in our original analysis) and worse verbal reasoning and concept formation (in our post-hoc adjusted sensitivity analysis) at 6-month follow-up, were part of multiple secondary analyses. These analyses were intended to be hypotheses-generating for future research.
The methods and results from this ancillary study may help inform future randomized trials in this field. Future trials could evaluate more lipophilic statins to more fully understand the potential effect of statins on delirium. In addition, such trials should include secondary outcomes measures to understand any benefits of reduced delirium, such as reduced length of stay and post-discharge cognitive impairment, as evaluated in this study. Moreover, this study and prior research may help inform development of a minimum set of outcome measures (i.e., a "core outcome set" (57)) for trials evaluating delirium in critically ill patients (see http://www.cometinitiative.org/studies/details/796). Such a core outcome set would be recommended for use in all trials in this field to facilitate comparison and synthesis of results across studies. Moreover, consideration of appropriate statistical methods to evaluate the effect of ICU-based interventions on the duration of delirium (when assessable -i.e. when patient is not in comatose state), accounting for the competing risks of death and ICU discharge, are important and the methodology in this study provides one example to consider. Lastly, future trials must consider striking a balance within the spectrum of efficacy versus effectiveness research in deciding about standardizing potentially important co-interventions (e.g. sedation) versus allowing routine practice to be used during the conduct of the trial.
Strengths and Limitations
This study has several strengths, including being an ancillary study embedded within a multicentered, randomized, double-blinded, placebo-controlled trial, and longitudinal detailed assessments of cognitive function at 6-and 12-month follow-up. However, there are also potential limitations. First, the primary outcome of delirium, assessed using the CAM-ICU screening instrument performed by trained research and clinical staff, was subject to both missing data and possible measurement error. However, the randomized nature of this study (with stratification by hospital site) and the statistical methods (including sensitivity analyses using multiple imputation of missing data) help reduce such concern. Second, rosuvastatin (compared to atorvastatin and simvastatin) has less antibacterial effects (58) and tissue penetration (given its lower lipophilic property). Hence, we cannot conclude that a different statin medication would not be beneficial. Experts have suggested that randomized trials of delirium evaluate both statins with higher and lower lipophilic properties given uncertainty regarding effects on neuroinflammation.(8) However, notably, both a lipophilic (i.e., simvastatin) and non-lipophilic (i.e., rosuvastatin) statin have been evaluated in large randomized trials of ARDS patients with similar findings of no beneficial effects on mortality and ventilatorfree days.(23;59) The SAILS trial selected rosuvastatin based on its relative superiority in terms of bioavailability, risk of hepatic dysfunction, and drug-drug interactions.(23) Third, relatively young ARDS patients with sepsis were enrolled; hence, these results may not generalize to other populations of critically ill patients. Fourth, there was no validated screening instrument used for excluding patients with pre-existing cognitive impairment from cognitive assessments at 6 and 12 month follow-up. However, the randomized comparison of rosuvastatin vs. placebo, the relatively high exclusion rate for baseline cognitive impairment (11% in our study versus 6% in a prior ICU study using a validated cognitive screening instrument (1) 
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Figure 3. Forest Plot of 6-Month Treatment Effect
This figure illustrates the treatment effect, presented as an effect size with 95% confidence interval for rosuvastatin versus placebo. Effect size was calculated as the treatment effect (Table 3 , difference in means or proportions) divided by the pooled standard deviation from the rosuvastatin and placebo groups.(62;63) 82 (50) 85 (52) 65 (47) 70 (52) 44 (53) 56 ( 142 (88) 137 (85) 120 (90) 116 (87) 68 (83) 92 ( Home independently 138 (84) 132 (80) 113 (82) 108 (80) 76 (92) 90 (85) Home with help 18 (11) 19 (12) 16 (12) 17 (13) 5 (6) 9 (8) Healthcare facility 7 (4) 14 (8) 7 (5) 10 (7) 2 (2) 7 ( (10) 31 (11) 32 (9) 31 (11) 33 (11) 32 ( 31 (19) 40 (24) 26 (19) 32 (24) 16 (19) 28 (26) Prior stroke with sequelae, No. (%) 1 (1) 3 (2) 1 (1) 2 (1) 0 (0) 2 (2) Baseline intensive care data APACHE III score 90 (27) 89 (28) 91 (27) 90 (28) 85 (27) 87 (28) PaO2/FiO2 ratio 168 (69) 172 (68) 171 (70) 171 (68) 172 (71) 117 (72) 112 (68) 96 (71) 93 (69) 58 (70) 79 ( 64 (39) 65 (39) 52 (38) 55 (41) 34 (41) 41 ( (66) 118 (72) 88 (65) 97 (72) 53 (64) ‡ 81 (77) ‡ Non-pulmonary infection 34 (21) 32 (20) 28 (21) 26 (19) 21 ( (53) 88 (53) 70 (52) 76 (56) 42 (51) (4) 10 (4) 9 (4) 10 (4) 11 (3) 11 ( (4) 13 (3) 12 (4) ‡ 13 (3) ‡ 13 (3) 13 (3) Coagulation 12 (4) 12 (4) 12 (4) 12 (4) 13 (3) 13 (2) Duration of mechanical ventilation, days 10 (9) 10 (11) 11 (10) 11 (12) 9 (7) 10 (10) ICU length of stay 14 (9) 13 (8) 14 (10) 13 (9) 13 (9) 12 (7) Hospital length of stay 21 (13) 21 (13) 22 (13) 22 (14) 21 (14) 20 (12) Abbreviations: APACHE III=acute physiology and chronic health evaluation III; PaO2=partial pressure of oxygen in arterial blood; FiO2=fraction of inspired oxygen; ICU=Intensive Care Unit.
*Proportions might not add to 100% because of rounding. Unknown or missing data for eligible cohort, delirium assessment cohort, and cognitive assessment cohort, respectively: race=6, 5, 3; APACHE III score=18, 15, 8; PaO2/FiO2=3, 2, 1; primary lung injury=2, 1, 1; vasopressor use=2, 2, 1; duration of mechanical ventilation=2, 0, 2; ICU length of stay=9, 6, 6 ; hospital length of stay=2, 2, 1. ** Statin use prior to hospital admission was available for a subset of patients. In this subset, the number and percentage of patients randomized to rosuvastatin vs. placebo for the each of the 3 cohorts described in the columns of this Table ( i.e., the "delirium and/or cognitive assessment" cohort, the "delirium data" cohort, and the "cognitive assessment" cohort) are: 21 (13%) 12 (24) 7 (10) 3.06 (1.00, 9.37) 0.050 Abbreviations: SD, standard deviation; 95% CI, 95% confidence interval; a Mean values (SD) are presented unless otherwise indicated. Details of test scoring: Hayling age-adjusted score (1-10, higher score is better); Verbal Fluency Test (higher score is better); and for Similarities, Digit Span, and Logical Memory I and II age-adjusted scores (1-19, higher score is better).Number of unknown or missing data for assessments performed at 6 months, by rosuvastatin and placebo groups, respectively: Cognitive impairment 0, 0; Hayling 0, 2; Verbal Fluency Test 1, 1; Similarities 1, 1; Digit Span 1, 1; Logical Memory I 3, 1; Logical Memory II 3, 4 b Calculated from linear or logistic regression models with random intercept and an indicator for treatment (rosuvastatin vs. placebo), time (12 vs. 6 month follow-up) and the interaction of treatment group and time. The treatment effect represents the mean difference in score for continuous measures (whereby a positive value represents better cognitive performance in the rosuvastatin group) and the odds ratio for binary measures (whereby a value >1 indicates worse cognitive performance in the rosuvastatin group).
Trauma as ARDS risk factor, n (%)
1 (1) 1 (1) 1 (1) (42) 65 (41) 48 (39) 56 (43) 36 (45) 40 (41) Corticosteroid use on day one, n (%) 35 (23) 35 (22) 29 (23) 30 (23) 15 (20) 22 (22) Lowest mean arterial pressure at randomization 59 (11) 60 (11) 59 (12) 60 (11) 58 (10) Abbreviations: APACHE III=Acute Physiology and Chronic Health Evaluation III; ICU=intensive care unit; ARDS=acute respiratory distress syndrome; PaO2=partial pressure of oxygen in arterial blood * The additional variables included in eTable 1 were based on prior publications. (1) (2) (3) In this cohort, 213 patients had all of the required data for the E-Pre-Deliric ICU delirium prediction model. (2) Comparing patients in the rosuvastatin vs. placebo, there was a 43% vs. 42% (p=0.576) predicted incidence of delirium, demonstrating similar balance of delirium risk between the two groups. ** Proportions might not add to 100% because of rounding. Unknown or missing data for eligible cohort, delirium assessment cohort, and cognitive assessment cohort, respectively: trauma as ARDS risk factor=2, 1, 1; metabolic acidosis= 17, 13, 10; blood urea nitrogen=1, 1, 0; alcohol dependence=47, 40, 27; smoking=30, 26, 14; albumin=53, 46, 33; corticosteroid= 19, 17, 15; mean arterial pressure=5, 4, 4; b Calculated from linear or logistic regression models with random intercepts for both hospital study site and patient and an indicator for treatment (rosuvastatin vs. placebo), time (12 vs. 6 month follow-up) and the interaction of treatment group and time. The treatment effect represents the mean difference in score for continuous measures (whereby a positive value represents better cognitive performance in the rosuvastatin group) and the odds ratio for binary measures (whereby a value >1 indicates worse cognitive performance in the rosuvastatin group). b Adjusted for: Acute Physiology and Chronic Health Evaluation III, age, cognitive impairment/dementia, hypertension, alcohol abuse, smoking, admission category, urgent admission, emergency surgery, metabolic acidosis, serum blood urea nitrogen, mean arterial pressure, and steroid use c Calculated from linear or logistic regression models with random intercept for patient and an indicator for treatment (rosuvastatin vs. placebo), time (12 vs. 6 month follow-up), the interaction of treatment group and time, and all adjustment variables described above. The treatment effect represents the mean difference in score for continuous measures (whereby a positive value represents better cognitive performance in the rosuvastatin group) and the odds ratio for binary measures (whereby a value >1 indicates worse cognitive performance in the rosuvastatin group).
d The model did not converge
